OncoMatch/Clinical Trials/NCT04644289
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Is NCT04644289 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including olaparib and durvalumab for epithelial ovarian cancer.
Treatment: olaparib · durvalumab — This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 any mutation
known (BReast CAncer) BRCA mutation and any histologic type
Allowed: BRCA2 any mutation
known (BReast CAncer) BRCA mutation and any histologic type
Disease stage
Required: Stage FIGO IIB, FIGO III, FIGO IV (FIGO)
Metastatic disease required
Grade: high-grade
Confirmed advanced (FIGO IIB/III/IV) high-grade, non-mucinous, non-clear cell epithelial ovarian, fallopian tube or primary peritoneal cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antineoplastic therapy
Prior antineoplastic therapy for ovarian, fallopian tube or primary peritoneal cancer
Cannot have received: systemic chemotherapy or radiotherapy
Exception: except for palliative reasons
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Cannot have received: concurrent chemotherapy, investigational medicinal product (IMP), biologic, or hormonal therapy for cancer treatment
Exception: concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
Any concurrent chemotherapy, investigational medicinal product (IMP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
Cannot have received: neoadjuvant chemotherapy
Patients planned for neoadjuvant chemotherapy or deemed unresectable at laparoscopy
Cannot have received: PARP inhibitor (olaparib)
Prior treatment with olaparib or any other poly [ADP-ribose] polymerase (PARP) inhibitor
Lab requirements
Blood counts
Haemoglobin ≥10.0 g/dL with no blood transfusion in the past 28 days; Absolute neutrophil count (ANC) ≥1.5×10^9/L; Platelet count ≥100×10^9/L
Kidney function
Creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test
Liver function
Total bilirubin ≤1.5 × institutional upper limit of normal (ULN); AST/ALT ≤2.5 × ULN unless liver metastases are present in which case they must be ≤5×ULN
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify